Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 16/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 16/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 16/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 16/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 16/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259214 | 0.83 | TNKS (0.49) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL13318641 | 0.81 | PIM3 (0.41) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL259304 | 0.79 | PIK3CA (0.54) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL259276 | 0.78 | GUSB (0.56) | IDO1TNKSTNKS2PARP2 | |
| SCHEMBL13318878 | 0.78 | PIM1 (0.40) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL259307 | 0.77 | TNKS2 (0.56) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL259355 | 0.76 | TNKS (0.56) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL259059 | 0.76 | ALDH1A1 (0.48) | PIK3CA | |
| SCHEMBL259329 | 0.74 | TNKS (0.42) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL4084278 | 0.73 | HPGD (0.65) | TNKSTNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | PIM1 865/4885CSNK2A2 237/4885CSNK2B 253/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PIM1 865/4885CSNK2A2 237/4885CSNK2B 253/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | PIM1 865/4885CSNK2A2 237/4885CSNK2B 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.